Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

A CT-based measure of spatial intratumoural heterogeneity is strongly associated with KRAS mutation status in lung adenocarcinoma, but a rigorous new study finds it adds no predictive power beyond ...

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...

BridgeBio Oncology's total equity value of $226 million is lower than its liquid assets of $344.1 million as of June 30. See ...

A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

Several factors — most notably, older age, treatment in the community setting , and a lower educational level in the area of residence — are associated with lower rates of microsatellite instability ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA (ctDNA)—strongly indicates a higher risk of cancer ...